01—Abstract
Summary
Summary of the 10-K/A filed March 28, 2012. Cited figures are marked; the original filing is the authoritative source.
This 10-K filing from Dexcom, Inc. (DXCM) for the fiscal year ended December 31, 2011, highlights the company's growth trajectory and its strategic focus on expanding product revenue while managing operating losses.
The company reported a significant increase in product revenue, reaching approximately $65.9 milliona, a 64% jump from the previous year, demonstrating strong commercial performance and market adoption. Dexcom's executive compensation strategy for 2011 emphasized conserving cash by favoring equity-based incentives over cash salaries, aiming to align employee interests with long-term stockholder value and support the company's goal of achieving profitability.
The filing also details the company's corporate governance structure, board of directors, and executive compensation policies, including details on base salaries, bonus plans, and equity awards, reflecting a pay-for-performance philosophy. The robust board composition, with a majority of independent directors, and the clear committee structures underscore a commitment to sound governance.
02—Key points
Key Highlights
- Product revenue increased by 64% year-over-year to approximately $65.9 million in fiscal year 2011, indicating strong market traction and sales growth.
- The company is focused on achieving profitability, evidenced by efforts to decrease operating losses while simultaneously increasing revenue.
- Executive compensation strategy prioritizes equity incentives over cash to conserve cash resources and align management interests with stockholders.
- Dexcom has a diverse and experienced board of directors, with a majority of independent directors, overseeing corporate governance and risk.
- The company's compensation committee uses a peer group analysis to set executive pay, targeting median compensation but rewarding outstanding performance with above-median payouts.
- Restricted Stock Units (RSUs) are a primary vehicle for long-term incentives and employee retention, favored over stock options to manage dilution.
- The audit committee actively oversees financial reporting and risk management, with the board appointing Dr. Jonathan Lord as an 'audit committee financial expert'.
03—One dollar
Follow one dollar
For each $1.00 of revenue in FY2011, Dexcom Inc lost $0.59.
- Revenue$76.3M100.0%
- Cost of revenue−$40.4M52.9%
- Gross profit$35.9M47.1%
- Operating costs−$80.7M105.8%
- Operating income−$44.8M58.7%
- Interest, other & tax$100,0000.1%
- Net income−$44.7M58.6%
04—Financials
Financial Highlights
Figures from 10-K/AFY2011filed March 28, 2012Financial Statements
FY2011 against FY2010
| Line item | FY2011FY2010 | Change |
|---|---|---|
| Revenue | $76.30M$48.60M | +57.0% |
| Cost of Revenue | $40.40M$30.20M | +33.8% |
| Gross Profit | $35.90M$18.40M | +95.1% |
| R&D Expenses | $29.60M$23.20M | +27.6% |
| SG&A Expenses | $51.10M$40.50M | +26.2% |
| Operating Expenses | $80.70M$63.70M | +26.7% |
| Operating Income | -$44.80M-$45.30M | +1.1% |
| Interest Expense | $0$1.50M | −100.0% |
| Net Income | -$44.70M-$55.20M | +19.0% |
| EPS (Basic) | $-0.17$-0.24 | +29.9% |
| Shares Outstanding (Basic) | 262.40M227.60M | +15.3% |
05—Questions
Frequently Asked Questions
What was Dexcom's revenue performance in 2011?
In fiscal year 2011, Dexcom reported a significant increase in product revenue, reaching approximately $65.9 million. This represents a substantial growth of 64% compared to the $40.2 million reported in 2010.
How does Dexcom structure its executive compensation?
Dexcom's executive compensation strategy for 2011 focused on conserving cash by emphasizing equity-based incentives (like Restricted Stock Units) over higher base salaries or cash bonuses. This approach aims to align executive interests with long-term stockholder value and support the company's goal of achieving profitability. Compensation is tied to performance against financial and operational goals.
What is the composition of Dexcom's Board of Directors?
Dexcom's Board of Directors is composed of experienced individuals with diverse backgrounds in healthcare, technology, and finance. A majority of the directors are considered independent, ensuring robust oversight. The Board has an Audit Committee, a Compensation Committee, and a Nominating and Governance Committee, each with specific responsibilities.
What is the company's approach to managing operating losses?
While focusing on revenue growth, Dexcom also prioritized decreasing its operating loss in 2011. This is reflected in their compensation structure, which included operating loss targets as a component of the annual bonus plan, incentivizing management to improve financial performance and move towards profitability.
06—Continue